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Nonreplicating, Cyst-Defective Type II Toxoplasma gondii Vaccine
Strains Stimulate Protective Immunity against Acute and Chronic
Infection
Barbara A. Fox, David J. Bzik
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA
Live attenuated vaccine strains, such as type I nonreplicating uracil auxotrophmutants, are highly effective in eliciting lifelong
immunity to virulent acute infection by Toxoplasma gondii. However, it is currently unknown whether vaccine-elicited immu-
nity can provide protection against acute infection and also prevent chronic infection. To address this problem, we developed
nonreverting, nonreplicating, live attenuated uracil auxotroph vaccine strains in the type IIku80 genetic background by target-
ing the deletion of the orotidine 5=-monophosphate decarboxylase (OMPDC) and uridine phosphorylase (UP) genes. Deletion of
OMPDC induced a severe uracil auxotrophy with loss of replication, loss of virulence in mice, and loss of the ability to develop
cysts and chronic infection. Vaccination of mice using type IIku80ompdcmutants stimulated a fully protective CD8 T cell-
dependent immunity that prevented acute infection by type I and type II strains of T. gondii, and this vaccination also severely
reduced or prevented cyst formation after type II challenge infection. Nonreverting, nonreplicating, and non-cyst-forming
ompdcmutants provide new tools to examine protective immune responses elicited by vaccination with a live attenuated type
II vaccine.
Toxoplasma gondii is an obligate intracellular parasite with anextremely broad host range inclusive of most birds and virtu-
ally all mammals (1). T. gondii chronically infects approximately
one-third of the human population (2). Three major strain types
are found inNorth America and Europe, and these type I, II, or III
strains differ with respect to their virulence traits inmice (3). Type
I strains are considered to be highly virulent, type II strains have
low virulence, and type III strains are considered to be avirulent.
Following acute infection by type II strains of T. gondii, a chronic
infection is established. Chronic infection is characterized by
slow-growing bradyzoite forms within tissue cysts in brain, mus-
cle, and eye (4), and infection is considered to be lifelong (5, 6).
Reactivated infection during AIDS or immune suppression may
cause a severe and difficult to treat toxoplasmic encephalitis (7) or
recurrent ocular toxoplasmosis (8). Vaccination against Toxo-
plasma is difficult due to the existence of multiple antigenically
distinct strain types and multiple antigenically distinct develop-
mental stages.Toxoplasma also can effectively escape immunity by
the development of a chronic encysted stage that is not easily
cleared by immune responses.
Antigen-based vaccine formulations provide only a partially
protective immunity and do not prevent the establishment of tis-
sue cysts and chronic infection following exposure toT. gondii (9).
Immunization with T. gondii extracts or killed noninvasive para-
sites also fails to elicit significant immunity to reinfection with T.
gondii (10, 11). Suboptimal vaccine priming using antigen-based
vaccine formulations is not surprising in view of the requirement
for populations of CD8 and CD4 T cells that produce the in-
terferon gamma (IFN-) that is necessary to establish immunity
and control of natural infection (12). In contrast to the subopti-
mal immunity elicited by antigen-based vaccines, immunization
with whole transgenic organisms elicits potent Th1-biased im-
mune responses associated with control of infection, and this vac-
cination strategy has enabled key experimental insights into host
responses that prime immunity (13).
Disruption of the de novo pyrimidine synthesis pathway has led
to remarkably effective vaccination strategies based on live atten-
uated uracil auxotroph vaccine strains (14). Disruption of car-
bamoyl phosphate synthetase II in the virulent type I RH strain
(the CPS mutant) induced a severe uracil auxotrophy (15, 16).
CPS is a live attenuated mutant that invades host cells normally
but fails to proliferatewithin its vacuole due to nutrient limitation,
and this loss of replication ability causes a complete absence of
virulence during infection (15). Disruption of the orotidine 5=-
monophosphate decarboxylase gene (OMPDC) in the virulent
type I RHku80 strain (17) also produced a nonreplicating uracil
auxotroph mutant that elicited protective immunity to virulent
acute infection (18). The extreme attenuation and avirulence of
type I T. gondii uracil auxotrophs are exemplified by survival of
severely immune-deficient IFN-/ knockout mice (15, 18, 19)
and interleukin-2 receptor  knockout (NOD/SCID/IL-2R/)
mice (20) that were infected with high-dose challenges of CPS.
Vaccination with CPS elicits a lifelong CD8 T cell-dependent
immunity against infection with type I strains (15, 18, 19, 21, 22).
This immunity is also effectively elicited in tyk2/ (23) or in
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MyD88/ signaling-deficient mice (24). Immunity elicited by
vaccination with CPS requires production of interleukin-12 (IL-
12) (24, 25), IFN- (15, 19), andCD8T cell populations (25, 26),
which possess cytolytic activity in vitro and in vivo (22). Previous
studies have implicated a key role for active T. gondii invasion of
host cells in mechanisms that promote T cell immunity to Toxo-
plasma (27–29). Recent studies using the CPS vaccination model
have found a role for active parasite invasion in the activation of
myeloid cells and the priming ofCD4 andCD8Tcell immunity
(30–32). Furthermore, phagocytosis of CPS by myeloid cells elic-
ited surprisingly insignificant CD4 and CD8 T cell responses
and ineffective immunity to Toxoplasma (21). In contrast, active
invasion of myeloid cells by CPS triggered potent CD4 and
CD8T cell responses and highly effective protective immunity to
Toxoplasma (21).
Previously, vaccination with CPS was shown to protect mice
against a virulent acute infection after challenge with a type I or
type II strain of T. gondii. However, this CPS vaccination did not
completely prevent the development of cysts and chronic infec-
tion in mice that were challenged with a type II strain (33). Here,
we developed nonreverting uracil auxotroph vaccine strains in the
type II ku80 genetic background by deleting the orotidine 5=-
monophosphate decarboxylase gene (OMPDC). The resulting
type II Pru ku80 ompdcmutants exhibit a severe uracil auxot-
rophy with loss of replication and virulence and undetectable cyst
formation. Vaccination of mice with the type II Pru ku80
ompdc mutant stimulates a potent protective immunity against
infection by type I and type II strains of Toxoplasma gondii.
MATERIALS AND METHODS
Primers. All oligonucleotide primers used in this study for plasmid con-
struction and PCR validation of genotypes of mutant strains are listed in
Tables S1 and S2 in the supplemental material.
Plasmid constructs. Yeast recombination was used to fuse 3 distinct
genetic elements (a 5= target flank, a hypoxanthine-xanthine-guanine
phosphoribosyltransferase gene [HXGPRT] selectable marker, and a 3=
target flank) in their correct order in the yeast shuttle plasmid vector
pRS416. This recombinationwas performedusing 29- to 36-bp crossovers
common to pRS416 and the HXGPRT selectable marker or to the gene
targeting flanks (see Table S1 in the supplementalmaterial) (18, 34). Gene
knockout targeting plasmids were engineered to delete a short region of
the gene’s predicted 5= untranslated region (UTR) and the entire pre-
dicted coding region of the targeted genomic locus (www.ToxoDB.org,
version 12.0). Targeting plasmids were first verified by restriction enzyme
digest and were sequenced to verify 100% gene homology to the available
type II ME49 genome sequence (17).
Plasmid pOMPP4 was constructed to delete nucleotides 2709536 to
2712859 in the OMPDC locus defined as TGME49_259690 (55.m04842)
on chrVIIb of the ToxoDB database. TheHXGPRTminigene cassette (35,
36) was fused between a 1,055-bp 5= genomic targeting flank and a 994-bp
3= genomic targeting flank amplified from DNA isolated from the Pru
ku80::HXGPRT strain (37).
Plasmid pOMPPC4 was constructed to remove HXGPRT from the
disrupted chromosomal OMPDC locus of the Pru ku80 ompdc::
HXGPRT strain. Plasmid pOMPP4 was digested with PmeI to remove
the HXGPRT cassette fragment followed by self-religation.
Plasmid pNUPP3 was designed to delete nucleotides 1497792 to
1500995 of the uridine phosphorylase (UP) locus on chrXI annotated as
TGME49_310640. The HXGPRT minigene cassette was fused between a
1,024-bp 5= targeting fragment and a 934-bp 3= targeting fragment.
Plasmid pgUPROMPwas designed to complement uracil auxotrophy
while disrupting the uracil phosphoribosyltransferase locus (UPRT). A
chromosomal segment of 3,258 bp corresponding to nucleotides 2712430
to 2709172 () on chrVIIb (the OMPDC gene) was flanked with a
1,151-bp 5=UPRT targeting DNA flank and a 1,119-bp 3=UPRT targeting
DNA flank. Plasmid pGUPROMT was designed to replace nucleotides
corresponding to 2718655 to 2722697 of the annotated UPRT chromo-
somal locus TGME49_312480 chrXI.
Strains, culture conditions, and PFU assays. The parental strains of
T. gondii used in this study are Pruku80::hxgprt and Pruku80hxgprt
(17). The RH strain (38), designated the RH(EP) strain (39), was used as
a virulent type I strain in challenge infections. All strains that were used or
developed in this study are listed in Table 1. Parasites were maintained by
serial passage in diploid human foreskin fibroblasts (HFF) at 35°C (40).
PFU assays were performed over 8 days (41) unless otherwise stated. Ura-
cil, uridine, cytidine, deoxyuridine, deoxycytidine, xanthine, mycophe-
nolic acid (MPA), and 5-fluorodeoxyuridine (FUDR)were obtained from
Sigma, Inc. 6-Thioxanthine (6TX) was obtained from Acros Organics
(Thermo Fisher Scientific).
Pyrimidine starvation viability assays. Pyrimidine auxotrophs were
serially diluted and inoculated into multiple 25-cm2 HFF flasks. Parasites
were allowed to invade for 2 h in uracil medium at 35°C, and cell mono-
layers were then rinsed 3 with cold phosphate-buffered saline (PBS) to
remove uracil and extracellular parasites. Infected cultures were incu-
bated for various periods of time without uracil to initiate uracil starva-
tion conditions, and then uracil was added back to the culture medium at
various times and PFU were scored 8 days later (18). The percentage of
initial viability remaining after different times of uracil starvation was
determined.
Genomic DNA isolation and PCR.Genomic DNAwas purified using
the DNA blood minikit (Qiagen). PCR products were amplified using a
4:1 mixture of Roche High Fidelity Expand Long and Expand Long Taq
polymerases.
Transformation of Toxoplasma gondii and knockout verification
strategy. Electroporations were performed on themodel BTX600 electro-
porator with 1.33 107 freshly isolated tachyzoites in the presence of15
g of linearized targeting plasmid DNA as described previously (17, 34,
37). Following selection of parasite clones, the genotype of the selected
clones was validated in PCR assays to measure the following: (i) PCR 1,
targeted deletion of the coding region of the targeted gene (DF and
DR primers); (ii) PCR 2, correct targeted 5= integration (CXF and
5=DHFRCXR primers); and (iii) PCR 3, correct targeted 3= integration
(3=DHFRCXF and CXR primers) using a previously described strategy
(34).
Single and double knockouts at the OMPDC (ompdc) and UP
(up) loci. The Pru ku80 hxgprt strain was transfected with SpeI-
linearized pOMPP4, or with SpeI-linearized pNUPP3, and knockouts
were continuously selected in MPA (25 g/ml), xanthine (250 M), and
uracil (250 M) to select and isolate the cloned Pru ku80 ompdc::
HXGPRT and Pru ku80 up::HXGPRT strains, respectively. To remove
the HXGPRT minigene cassette from the Pru ku80 ompdc::HXGPRT
TABLE 1 Strains used in this study
Strain characteristic(s) Parent strain characteristic(s)
Source or
reference
RH RH(ERP) 38, 41
RH ku80 ompdc::HXGPRT RH ku80 hxgprt 18
Pru ku80::HXGPRT Pru hxgprt 37
Pru ku80 hxgprt Pru ku80::HXGPRT 37
Pru ku80 ompdc::HXGPRT Pru ku80 hxgprt This study
Pru ku80 up::HXGPRT Pru ku80 hxgprt This study
Pru ku80 ompdc hxgprt Pru ku80 ompdc::HXGPRT This study
Pru ku80 ompdc
up::HXGPRT
Pru ku80 ompdc hxgprt This study
Pru ku80 ompdc::HXGPRT
uprt::gOMPDC
Pru ku80 ompdc::HXGPRT This study
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strain, parasites were transfected with SpeI-linearized pOMPPC4 and se-
lected in 6TX (250 g/ml) and uracil (250 M). The Pru ku80 ompdc
hxgprt strain was validated using PCR 4 with a forward primer
(CLOMF) designed into the 3= side of the 5= targeting flank and the CXR
primer. The Pruku80ompdchxgprt strain was transfected with SpeI-
linearized pNUPP3 to isolate the Pruku80ompdcup::HXGPRT dou-
ble mutant strain following selection in MPA and xanthine.
Functional complementation of the RH ku80 ompdc::HXGPRT
strain. The Pru ku80 ompdc::HXGPRT strain was transfected with
PmeI-linearized plasmid pgUPROMP containing the 3,258-bp genomic
OMPDC gene. Following transfection, the culture was maintained in the
presence of uracil (250 M) for 24 h, and then uracil medium was re-
moved, and the selection was continued in the absence of uracil. Parasites
emerging from this selection were subcloned, and individual isolates were
evaluated for their genotype to verify targeted deletion of UPRT and the
simultaneous insertion of a functional allele of OMPDC at the UPRT
locus. The genotype of the expected gene replacement at the UPRT locus
was verified using PCR5 tomeasure the deletion of theUPRT locus and by
using PCR 6 and 7 to assay for correct 5= and 3= targeted integration of the
genomic allele ofOMPDC (using primers UPRTCXF with OMXEXR and
OMXEXFwithUPRTCXR). Individual clonal isolates were also examined
for functional deletion ofUPRT bymeasuring resistance to 50MFUDR
to demonstrate loss of UPRT activity.
Mice, immunizations, T cell depletion, and challenge infections.
Adult 6- to 8-week-old C57BL/6 and IFN-/ knockout mice (002287)
were obtained fromThe JacksonLaboratory (BarHarbor,ME).Micewere
maintained at the Dartmouth-HitchcockMedical Center (Lebanon, NH)
mouse facility, and mice were cared for and handled according to Animal
Care and Use Program of Dartmouth College using National Institutes of
Health-approved Institutional Animal Care and Use Committee guide-
lines. Mice were immunized twice 14 days apart with 3 106 tachyzoites
by intraperitoneal injection. Purified anti-CD8 (clone 2.43) and isotype
control (rat IgG2a) antibodies were purchased from BioXCell. Antibody
(500g) was administered 1 day prior to challenge infections, and 250g
of antibodywas administered 0 and 3 days after challenge infection. CD8
T cells were depleted by greater than 99%. Challenge infections were per-
formed 30 days after vaccination.
Cyst burden measurements. Brain cyst burdens were determined as
previously described (33, 37). The Pruku80 background expresses green
fluorescent protein (GFP) under the control of a bradyzoite-specific
LDH2 promoter. Cysts were screened at 150 magnification to detect
GFP bradyzoites encased within a cyst wall structure.
Statistical analysis. Unless noted otherwise, all experiments were re-
peated at least two times and results were similar between repeats. Statis-
tical analysis was performed using Graphpad Prism 6 software. Data for
PFU and cyst analysis was calculated using the 2-tailed unpaired Student t
test. Student t tests were conducted under the assumption of equal vari-
ance. Survival experiments were analyzed using the log-rankMantel-Cox
test. A P value of 	0.05 was considered to be statistically significant. P
values of0.05, 0.01, 0.001, or 0.0001 are indicated by *, **, ***, and ****,
respectively, in Fig. 5 to 7.
RESULTS
Type II pyrimidine pathwaymutants. To functionally define the
predicted roles of the de novo pyrimidine synthesis and the pyrim-
idine salvage pathways (Fig. 1) in type II strains of T. gondii, we
targeted the last enzymatic activity of the de novo pathway en-
coded by the orotidine monophosphate decarboxylase (OMPDC)
gene that produces uridine-5=-monophosphate (UMP) from oro-
tidine-5=-monophosphate to establish the pyrimidine nucleotide
pool (14, 18). The Pruku80hxgprt strain was targeted to delete
the OMPDC gene to develop the Pru ku80 ompdc::HXGPRT
mutant (Fig. 2A). The uridine phosphorylase (UP) gene encodes
the salvage enzyme that converts uridine or deoxyuridine to uracil
(42, 43) prior to its being salvaged into the nucleotide pool by
conversion of uracil to UMP via the uracil phosphoribosyltrans-
ferase (UPRT) enzyme activity (Fig. 1) (39). The UP gene was
deleted using a similar targeting strategy (Fig. 2A) to develop the
Pru ku80 up::HXGPRT mutant. The Pru ku80 ompdc::
HXGPRT mutant was then retargeted at the deleted OMPDC lo-
cus to excise the HXGPRT selectable marker to develop the Pru
ku80 ompdc hxgprtmutant (Fig. 2B), which was retargeted
to delete the UP locus to develop the Pru ku80 ompdc up::
HXGPRT double mutant (Table 1). The ompdc up double
mutant was developed to assess the ability of type II strains to
salvage pyrimidine nucleosides from the host.
Functional analysis of pyrimidine synthesis and salvage in
type II T. gondii. The type II ompdc, up, and ompdc up
strains were examined in PFU assays under various growth con-
ditions to assess parasite growth and nutrient rescue profiles. The
upmutant and the parental Pruku80 strains replicate normally
in the absence or in the presence of uracil, uridine, or cytidine
(data not shown). In contrast, the type II ompdc (Fig. 3A) and
ompdc up (Fig. 3B) mutants exhibited a severe uracil auxotro-
phy and replication deficiency in the absence of uracil supplemen-
tation. In contrast to the complete rescue of growth observed with
uracil supplementation (Fig. 3A and B), the replication of the Pru
ompdc mutant was only weakly rescued with high concentra-
tions of uridine, as shown by the formation of very small plaques
(Fig. 3C). In addition, the replication of the Pru ompdc mutant
FIG 1 Pyrimidine synthesis and salvage pathways in Toxoplasma gondii. The
six-step de novo pyrimidine synthesis pathway (red) and the pyrimidine sal-
vage enzyme pathway (blue) show both pathways produce uridine-5=-mono-
phosphate (UMP) (boxed). Intermediate metabolites are shown (phosphori-
bosyl-1-pyrophosphate [PRPP]). (Top) The biosynthetic enzymes mediating
each step of the de novo pathway are carbamoyl phosphate synthetase II
(CPSII), aspartate carbamoyltransferase (ACT), dihydroorotase (DHO), dihy-
droorotate dehydrogenase (DHODH), orotate phosphoribosyltransferase
(OPRT), and orotidine-5=-monophosphate (OMP) decarboxylase (OMPDC).
(Bottom) The pyrimidine salvage enzymes mediating each step of the salvage
pathway are cytidine deaminase (CTD), uridine phosphorylase (UP), and ura-
cil phosphoribosyltransferase (UPRT).
Fox and Bzik
2150 iai.asm.org May 2015 Volume 83 Number 5Infection and Immunity
was not significantly rescued in high concentrations of cytidine
(Fig. 3C). Similar rescue profiles were observed using deoxyuri-
dine and deoxycytidine, respectively (data not shown). The Pru
ompdc up double mutant was not detectably rescued by addi-
tion of either uridine or cytidine (Fig. 3D), indicating that pyrim-
idine pathways in type II strains mirror the pathways known to
exist in type I strains (18). However, the rescue of growth in type II
strains using uridine or cytidine supplementation was reduced in
comparison to rescue of the corresponding type I mutants, sug-
gesting a reduced pyrimidine salvage capacity for pyrimidine
nucleosides is present in type II strains.
Complementation of type II pyrimidine auxotrophy. The
Pru ompdc mutant was complemented by insertion of a func-
tional wild-type allele of theOMPDC gene at theUPRT locus (Fig.
4A). The Pruku80ompdc::HXGPRTuprt::gOMPDC comple-
mented strain was resistant to FUDR (data not shown), and the
growth rate of the complemented strain was normal whether ura-
cil was absent or present in the culture medium (Fig. 4B).
Pyrimidine starvation. PFU assays were used to measure how
rapidly type II pyrimidine auxotrophs lost viability intracellularly
under conditions of uracil starvation. When subjected to uracil
starvation, the Pru ompdc up mutant lost viability at a mark-
edly higher rate than the Pruompdcmutant (data not shown). In
addition, the type II Pru ompdcmutant lost viability at a signif-
icantly higher rate than the corresponding type I RHompdcmu-
tant (Fig. 5).
Pyrimidine biosynthesis is required for type II virulence
and cyst development. While the Pru ku80::HXGPRT strain
exhibits an 75% lethal dose (LD75) after a 2  10
5-tachyzoite
challenge dose (Fig. 6A) and is uniformly lethal at higher doses
(Fig. 6), C57BL/6 mice infected with the type II Pru ku80
ompdc::HXGPRTmutant did not exhibit acute virulence or signs
of infection after receiving challenge doses of 2  105 (Fig. 6A),
2 106 (Fig. 6B), or 2 107 (Fig. 6C) tachyzoites, and IFN-/
knockout mice survived a 2  105 challenge dose (Fig. 6D). In
contrast, the complemented Pru ku80 ompdc::HXGPRT
uprt::gOMPDC strain exhibited the same acute virulence pheno-
type as the Pru ku80::HXGPRT strain (Fig. 6).
Mice infected with 200 or 2 106 tachyzoites of the Pruku80
ompdc::HXGPRTmutant failed to establish detectable brain cyst
burdens by 3 weeks postinfection (Fig. 6E). (Three weeks postin-
fection is the peak time point of cyst formation in the Pru ku80
FIG 2 Targeted gene deletion at the orotidine 5=-monophosphate decarbox-
ylase locus (OMPDC). (A) Strategy for deletion and validation of the endoge-
nous OMPDC locus via targeted integration of the HXGPRT marker at the
OMPDC locus of the Pruku80hxgprt strain. Approximate locations of PCR
products used to validate genotypes are depicted. The Pru ku80 hxgprt
parental strain was positive for the PCR 1 product, while the targetedOMPDC
knockout was positive for PCR 2 and PCR 3 (see Materials and Methods). (B)
Strategy for cleanup of the deleted OMPDC locus. The HXGPRT marker was
removed from the disrupted OMPDC locus using the depicted strategy that
utilized the ability to negatively select against theHXGPRTmarker using 6TX
selection. Successfully cleaned up strains withHXGPRT deletedwere validated
using PCR 4 (see Materials and Methods).
FIG 3 Functional rescue of type II Toxoplasma gondii uracil auxotrophs. Ap-
proximately 100 tachyzoites of the Pruku80ompdc::HXGPRT (A and C) or
Pru ku80 ompdc up::HXGPRT (B and D) strain were inoculated into a
PFU assay in the absence of pyrimidine supplementation (A and B), in the
presence of uracil supplementation (200 M) (A and B), in the presence of
uridine supplementation (200 M) (C and D), or in the presence of cytidine
supplementation (200 M) (C and D) of the growth medium. The culture
monolayer was stained 8 days later to reveal PFU and HFF monolayers.
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background [37].) Cysts were also not detected in mice infected
with thismutant or the Pruku80ompdcup::HXGPRT double
mutant at any time point evaluated up to 7 weeks postinfection
(data not shown). In contrast, mice infected with 200 tachyzoites
of the complemented Pru ku80 ompdc::HXGPRT uprt::
gOMPDC strain exhibited typical cyst burdens compared to the
Pru ku80::HXGPRT strain (Fig. 6E). In addition, cysts were not
detected inmice that survived the 2 107 challenge dose (Fig. 6C)
of the Pru ku80 ompdc::HXGPRT mutant (Fig. 6E). Collec-
tively, these results demonstrate that type II uracil auxotrophmu-
tants exhibit an avirulent phenotype and a severe defect in their
ability to establish cysts and chronic infection.
Type II pyrimidine auxotrophs elicit protective immunity
against type I and type II T. gondii infection.We examined type
II pyrimidine auxotrophs as live attenuated vaccine strains.
C57BL/6 mice were vaccinated with the Pru ku80 ompdc::
HXGPRT strain, and 30 days later, mice were challenged with
1,000 tachyzoites of virulent type I strain RH (LD1000) (Fig. 7A).
All Pruku80ompdc::HXGPRT-vaccinatedmice survived type I
virulent challenge infection, whereas no naive unvaccinated mice
survived the challenge infection. We also evaluated protection
from type II infection. Pru ku80 ompdc::HXGPRT-vaccinated
mice survived a type II virulent challenge of 2  107 tachyzoites,
whereas no naive unvaccinated mice receiving this challenge dose
survived (Fig. 7B). We performed CD8 T cell depletion experi-
ments to determine whether this protective immunity was depen-
dent on CD8 T cell populations. Vaccinated mice depleted of
CD8 T cells rapidly succumbed to type II challenge infection,
whereas vaccinated mice treated with control isotype antibody
survived challenge infection (Fig. 7C). In addition, 31 days after
type II challenge infection, we examined the brains of mice that
survived type II challenge infection to assess whether brain cysts
(chronic infection) were present.While naivemice that received a
200-tachyzoite challenge of the Pru ku80::HXGPRT strain pro-
duced high numbers of cysts, cyst burdens were not detected in
Pru ku80 ompdc::HXGPRT-vaccinated mice that were rechal-
lenged with 2 107 tachyzoites of the Pru ku80::HXGPRT strain
(Fig. 7D).
DISCUSSION
Type I uracil auxotroph vaccines were previously described to
stimulate potent T cell-mediated immunity to virulent type I chal-
lenge infection (15, 18, 19, 21–24). While the type I CPS uracil
auxotroph vaccine also protected vaccinated mice from virulent
type II challenge infection and reduced chronic infection (cyst
burdens) by98%, vaccinated mice were incompletely protected
from chronic infection (33). Our results using a nonreverting,
nonreplicating, type II vaccine strain suggest that vaccinationwith
a type II strain may provide a more secure immunity to type II
infection by preventing cyst development and chronic infection.
Type II uracil auxotroph vaccines protected mice from infection
by both type I and type II strains.
Our investigation of pyrimidine auxotrophy in the type II
background of T. gondii indicates that the pyrimidine synthesis
and salvage pathways mirror the pathways previously reported in
type I strains (14–16, 18). The uridine phosphorylase activity of
type II is used to some extent for physiological salvage of uridine
and deoxyuridine based on the observation of the formation of
very small plaqueswhen using either of these nucleosides to rescue
the growth of the Pru ku80 ompdc::HXGPRT vaccine strain.
While visible plaques were observed in type I uracil auxotrophs
using biochemical rescues with cytidine or deoxycytidine (18),
visible plaques were not observed after cytidine or deoxycytidine
rescue of the type II uracil auxotrophs in plaque assays. However,
inspection of these cultures prior to staining did reveal tiny zones
of infection involving just several infected cells without detectable
FIG 4 Complementation of the Pru ompdcmutant. (A) Strategy for com-
plementation of the Pru ompdc mutant by simultaneous knockout of
UPRT and targeted insertion of the genomic allele of OMPDC at the UPRT
locus. The Pru ku80 ompdc::HXGPRT strain was transfected with plas-
mid pGUPROMP and parasites that were complemented for de novo py-
rimidine biosynthesis were selected by growth in media without uracil
supplementation. Approximate locations of PCR validation product PCR 5
(targeted deletion ofUPRT), and PCR 6 and PCR 7 (targeted integration of
the genomic allele of OMPDC) are shown (see Materials and Methods).
Correctly targeted replacement clones were positive for the PCR 6 and PCR
7 products and were negative for PCR 5. (B) Functional rescue of comple-
mented strain Pru ku80 ompdc::HXGPRT uprt::gOMPDC. Approxi-
mately 100 tachyzoites of the Pru ku80 ompdc::HXGPRT uprt::
gOMPDC strain were assayed in an 8-day PFU assay in the absence (no
addition) or presence of uracil.
FIG 5 Pyrimidine starvation causes a rapid loss of parasite viability in type I
and type II uracil auxotrophs. PFU assays were used to measure how rapidly
pyrimidine auxotrophs lost viability intracellularly under conditions of pyrim-
idine starvation in a 5-day starvation assay. Viability profiles for the type II Pru
ku80 ompdc::HXGPRT mutant (solid circles) and the type I RH ku80
ompdc::HXGPRTmutant (open squares) are shown. *, P	 0.05.
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lysis of the monolayer. These results suggest that cytidine and
deoxycytidine can be converted by type II strains into uridine or
deoxyuridine, respectively, by the action of a cytidine deaminase
activity. Nonetheless, the ability to rescue type II uracil auxo-
trophs with pyrimidine nucleosides was notably reduced in com-
parison to rescue profiles previously reported for type I uracil
auxotrophs (18). In addition, we demonstrated that pyrimidine
starvation also occurs at a higher rate in type II uracil auxotrophs
than in corresponding type I mutants. Together, these results in-
dicate that type II strains rely more heavily on the de novo pyrim-
idine synthesis pathway due to a reduced capacity to salvage py-
rimidine nucleosides by comparison to type I uracil auxotroph
mutants (18).While these findingsmay be explained by a reduced
metabolic capacity at the cytidine deaminase, uridine phosphor-
ylase, or uracil phosphoribosyltransferase steps of salvage (18), it
is possible that this metabolic difference may also be affected by
the inherent capacity of type I and type II strains to transport
nutrients from the host cell into the vacuole or into the parasite,
where nucleobases and nucleosides become available for incorpo-
ration into the UMP pool.
Deletion of OMPDC in the type II background of T. gondii
induced a severe uracil auxotrophy, with loss of replication and
loss of virulence in mice. Furthermore, cyst burdens and chronic
infection were not established following high-dose infection or
vaccination of mice with type II ompdc uracil auxotroph mu-
tants. Vaccination of mice with the Pru ku80 ompdc mutant
stimulated a fully protective CD8 T cell-dependent immunity
that prevented virulent acute infection by type I and type II strains
of T. gondii, and this vaccination also severely reduced or poten-
tially prevented cyst formation after type II challenge infection in
C57BL/6 mice. In our cyst burden analysis after challenge infec-
tions, we scored 50% of the brain homogenates for cysts using
dark-field microscopy to detect GFP cysts. Extremely low-level
cyst burdensmay be present, althoughwe estimate cyst burdens in
rechallenged vaccinated mice to be below 1 cyst per brain.
Acute virulence in type I T. gondii uracil auxotrophs is attenu-
ated by at least 8 logs (18), and type II uracil auxotroph virulence
appears to be similarly attenuated. Type I uracil auxotrophs were
previously demonstrated to elicit remarkably potent CD4 and
CD8 T cell responses following vaccination of mice (15, 18-25,
27, 30-33). Consequently, nonreverting, nonreplicating, and non-
cyst-forming ompdc type II uracil auxotroph mutants provide
new and improved vaccination tools to elicit protective immunity
FIG 6 Pyrimidine biosynthesis is required for type II virulence and cyst de-
velopment. Groups (n
 8) of C57BL/6mice were inoculated i.p. with (A) 2
105 tachyzoites, (B) 2 106 tachyzoites, or (C) 2 107 tachyzoites of the Pru
ku80::HXGPRT strain (solid squares), the Pru ku80 ompdc::HXGPRT
mutant (open circles), or the complemented Pru ku80 ompdc::HXGPRT
uprt::gOMPDC strain (solid circles), and survival wasmonitored for 30 days.
(D) IFN-/ knockoutmice (n
 4)were infectedwith 2 105 tachyzoites of
the parental Pru ku80::HXGPRT strain (solid squares) or the Pru ku80
ompdc::HXGPRT mutant (open circles), and survival was monitored for 30
days (single experiment). (E) Cyst burdens in the brains of infected mice.
Groups (n 
 8) of mice were inoculated with 200 tachyzoites of the Pru
ku80::HXGPRT parental strain, with 200 tachyzoites of the complemented
Pru ku80 ompdc::HXGPRT uprt::gOMPDC strain, or with 200 or 2 106
tachyzoites of the Pru ku80 ompdc::HXGPRT mutant, and cyst burdens
were determined 3 weeks postinfection. Cyst burdens were also determine in
mice infected with 2  107 tachyzoites of the Pru ku80 ompdc::HXGPRT
mutant 31 days postinfection. **, P	 0.01; ***, P	 0.001; ****, P	 0.0001.
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to T. gondii and to examine the host immune responses that are
elicited by vaccinationwith a live attenuated type II vaccine strain.
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